Wasatch Advisors LP Buys 223,217 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS)

Wasatch Advisors LP raised its holdings in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 47.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 696,318 shares of the company's stock after acquiring an additional 223,217 shares during the period. Wasatch Advisors LP owned approximately 2.87% of OrthoPediatrics worth $16,141,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP lifted its position in OrthoPediatrics by 20.2% during the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock valued at $24,601,000 after purchasing an additional 178,078 shares during the last quarter. Kennedy Capital Management LLC increased its stake in OrthoPediatrics by 129.8% in the fourth quarter. Kennedy Capital Management LLC now owns 249,978 shares of the company's stock valued at $5,794,000 after acquiring an additional 141,174 shares during the last quarter. Mutual of America Capital Management LLC raised its position in OrthoPediatrics by 57.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 169,021 shares of the company's stock valued at $3,918,000 after purchasing an additional 61,412 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in OrthoPediatrics by 204.8% during the fourth quarter. JPMorgan Chase & Co. now owns 42,817 shares of the company's stock worth $992,000 after purchasing an additional 28,768 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new position in shares of OrthoPediatrics in the 4th quarter worth about $528,000. Hedge funds and other institutional investors own 69.05% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KIDS shares. Lake Street Capital assumed coverage on OrthoPediatrics in a research note on Monday, April 7th. They issued a "buy" rating and a $37.00 target price for the company. Truist Financial decreased their price target on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Needham & Company LLC reissued a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a research report on Wednesday, April 9th. Finally, Stifel Nicolaus decreased their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $37.00.

OrthoPediatrics Trading Up 0.7 %

Shares of KIDS traded up $0.14 during mid-day trading on Tuesday, hitting $20.66. 16,844 shares of the company's stock traded hands, compared to its average volume of 197,664. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $501.77 million, a P/E ratio of -16.80 and a beta of 1.17. The business's 50-day moving average price is $23.72 and its 200-day moving average price is $24.49. OrthoPediatrics Corp. has a 1 year low of $20.26 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The business had revenue of $52.67 million during the quarter, compared to analyst estimates of $51.16 million. During the same period in the prior year, the business earned ($0.23) EPS. As a group, sell-side analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $132,006.60. Following the completion of the transaction, the general counsel now owns 110,767 shares of the company's stock, valued at approximately $2,753,667.62. This represents a 4.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Fred Hite sold 6,443 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $160,172.98. Following the completion of the sale, the chief financial officer now directly owns 207,989 shares in the company, valued at approximately $5,170,606.54. The trade was a 3.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,732 shares of company stock worth $589,978 over the last three months. Company insiders own 31.80% of the company's stock.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.